Promising Pain Relief with Injectable Allograft for Chronic Low Back Pain What should readers take away from your report?

Response: Sixty percent of patients who received allograft treatment for their chronic low back pain reported an improvement of greater than 50% in pain, and 70% reported more than a 20-point improvement in their ODI scores which is a full category or more of functional improvement. There were no persistent adverse events reported. Such improvements are very promising for patients living with chronic low back pain. This treatment may help them return to normal activity for a longer period of time than is possible with other treatments for this condition. What recommendations do you have for future research as a result of this study?

Response: We need to continue to research the efficacy of injectable allograft treatments, as the initial results are promising. In addition, use of allograft may help decrease opioid use in patients with chronic low back pain, which could be especially meaningful for younger patients who would have many years of high level  function and better quality of life ahead. Is there anything else you would like to add? Any disclosures?

The treatment requires no incisions, and patients are able to go home on the same day.

VIVIEX Biologics, Inc. sponsored this study, and I serve as a medical consultant for them.


 Viable disc allograft supplementation in patients with chronic low back pain (VAST Trial): Interim 36- month results of an open-label extension study

Society of Interventional Radiology’s 2023 Annual Scientific Meeting

The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on March 4, 2023 by